Mice with constitutively active K-ras and Tgfb2r deletion specifically in the pancreatic cells (KrasG12D+Tgfbr2−/− mice) develop aggressive pancreatic carcinoma at 6–7 weeks of age9. The gene discussed is KRAS; the disease is exocrine pancreatic carcinoma.